Los sanitarios alemanes rechazan la vacuna. +60% en algunas regiones

#10 https://www.fda.gov/media/144434/download

El apply de Pfizer a la FDA para su vacuna, ahí hay muchos datos. No se si se sabe mucho más a día de hoy.

8.3 Known Risks
The vaccine elicited increased local and systemic adverse reactions as compared to those in
the placebo arm, usually lasting a few days. The most common solicited adverse reactions were
pain at injection site (91.6%), fatigue (68.5%), headache (63.0%), muscle pain (59.6%), joint
pain (44.8%), and chills (43.4%). Adverse reactions characterized as reactogenicity were
generally mild to moderate; 0.2% to 9.7% of these events were reported as severe, with severe
solicited adverse reactions being more frequent after dose 2 than after dose 1 and generally
less frequent in older adults (≥65 years of age) as compared to younger participants. Among
reported unsolicited adverse events, lymphadenopathy occurred much more frequently in the
vaccine group than the placebo group and is plausibly related to vaccination. The number of
participants reporting hypersensitivity-related adverse events was numerically higher in the
vaccine group compared with the placebo group (258 events in 233 participants [1.5%] vs. 185
events in 166 participants [1.1%]). There were no anaphylactic or severe hypersensitivity
reactions with close temporal relation to the vaccine.
Serious adverse events, while uncommon (1.0% in both treatment groups), represented medical
events that occur in the general population at similar frequency as observed in the study. Of the
7 SAEs in the mRNA-1273 group that were considered as related by the investigator, FDA
considered 3 as related: intractable nausea and vomiting (n=1), facial swelling (n=2). For the
serious adverse events of rheumatoid arthritis, peripheral edema/dyspnea with exertion, and
autonomic dysfunction, a possibility of vaccine contribution cannot be excluded. For the event of
B-cell lymphoma, an alternative etiology is more likely. An SAE of Bell’s palsy occurred in a
vaccine recipient, for which a causal relationship to vaccination cannot be concluded at this
time.
No specific safety concerns were identified in subgroup analyses by age, race, ethnicity,
medical comorbidities, or prior SARS-CoV-2 infection.